CRL
$191.81
Revenue | $1009.76Mn |
Net Profits | $68.68Mn |
Net Profit Margins | 6.8% |
Charles River Laboratories International’s revenue fell -1.64% since last year same period to $1009.76Mn in the Q3 2024. On a quarterly growth basis, Charles River Laboratories International has generated -1.59% fall in its revenue since last 3-months.
Charles River Laboratories International’s net profit fell -21.41% since last year same period to $68.68Mn in the Q3 2024. On a quarterly growth basis, Charles River Laboratories International has generated -23.68% fall in its net profits since last 3-months.
Charles River Laboratories International’s net profit margin fell -20.1% since last year same period to 6.8% in the Q3 2024. On a quarterly growth basis, Charles River Laboratories International has generated -22.44% fall in its net profit margins since last 3-months.
EPS Estimate Current Quarter | 2.43 |
EPS Estimate Current Year | 2.43 |
Charles River Laboratories International’s earning per share (EPS) estimates for the current quarter stand at 2.43 - a 1.67% jump from last quarter’s estimates.
Charles River Laboratories International’s earning per share (EPS) estimates for the current year stand at 2.43.
Earning Per Share (EPS) | 2.59 |
Charles River Laboratories International’s earning per share (EPS) fell -4.78% since last year same period to 2.59 in the Q3 2024. This indicates that the Charles River Laboratories International has generated -4.78% annual rate of fall in its earning per share (EPS) in the last 4 quarters.
Earnings Date | Estimated EPS | Reported EPS | Surprise % |
---|---|---|---|
2024-05-09 | 2.07 | 2.27 | 9.66% |
2024-11-06 | 2.43 | 2.59 | 6.58% |
2024-08-07 | 2.39 | 2.8 | 17.15% |